Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director-related transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a minor increase in shareholding by a connected person of Executive Director Sir Andrew Witty. On October 13, 2015, 5 GSK Ordinary Shares were acquired at a price of 1,319.64 pence per share. This acquisition resulted from the re-investment of dividends paid to shareholders on October 1, 2015, within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share transaction described above.
Investor Verification Checklist
- Verify the total shareholding of Sir Andrew Witty and his connected persons following this transaction.
- Confirm the dividend payment date of October 1, 2015, and the associated reinvestment terms.
- Review the share price of 1,319.64 pence against the market price on October 13, 2015.
- Check for any other pending director transactions not covered in this specific notification.